Literature DB >> 10435616

PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.

W Wick1, F B Furnari, U Naumann, W K Cavenee, M Weller.   

Abstract

The tumor suppressor gene PTEN (MMAC1, TEP1) encodes a dual-specificity phosphatase and is considered a progression-associated target of genetic alterations in human gliomas. Recently, it has been reported that the introduction of wild type PTEN into glioma cells containing endogenous mutant PTEN alleles (U87MG, LN-308), but not in those which retain wild-type PTEN (LN-18, LN-229), causes growth suppression and inhibits cellular migration, spreading and focal adhesion. Here, we show that PTEN gene transfer has no effect on the chemosensitivity of the four cell lines. Further, a correlational analysis of the endogenous PTEN status of 12 human glioma cell lines with their sensitivity to seven different cancer chemotherapy drugs reveals no link between PTEN and chemosensitivity. In contrast, ectopic expression of wild type PTEN, but not the PTEN(G129R) mutant, in PTEN-mutant gliomas markedly sensitizes these cells to irradiation and to CD95-ligand (CD95L)-induced apoptosis. PTEN-mediated facilitation of CD95L-induced apoptosis is associated with enhanced CD95L-evoked caspase 3 activity. Protein kinase B (PKB/Akt), previously shown to inhibit CD95L-induced apoptosis in nonglial COS7 cells, is inactivated by dephosphorylation. Interestingly, both PTEN-mutant U87MG and PTEN-wild-type LN-229 cells contain phosphorylated PKB constitutively. Wild-type PTEN gene transfer promotes dephosphorylation of PKB specifically in U87MG cells but not in LN-229 cells. Sensitization of U87MG cells to CD95L-apoptosis by wild-type PTEN is blocked by insulin-like growth factor-1 (IGF-1). The protection by IGF-1 is inhibited by the phosphoinositide 3-OH (PI 3) kinase inhibitor, wortmannin. Although PKB is a down-stream target of PI 3 kinase, the protection by IGF-1 was not associated with the reconstitution of PKB phosphorylation. Thus, PTEN may sensitize human malignant glioma cells to CD95L-induced apoptosis in a PI 3 kinase-dependent manner that may not require PKB phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435616     DOI: 10.1038/sj.onc.1202774

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Gene therapy for brain tumors.

Authors:  K Bansal; H H Engelhard
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets.

Authors:  A Shir; A Levitzki
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

3.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

Authors:  Brian McEllin; Cristel V Camacho; Bipasha Mukherjee; Brandon Hahm; Nozomi Tomimatsu; Robert M Bachoo; Sandeep Burma
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

4.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Contribution of growth and cell cycle checkpoints to radiation survival in Drosophila.

Authors:  Burnley Jaklevic; Lyle Uyetake; Willy Lemstra; Julia Chang; William Leary; Anthony Edwards; Smruti Vidwans; Ody Sibon; Tin Tin Su
Journal:  Genetics       Date:  2006-10-08       Impact factor: 4.562

6.  Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

Authors:  Yan Shi; Xuesong Liu; Edward K Han; Ran Guan; Alexander R Shoemaker; Anatol Oleksijew; Keith W Woods; John P Fisher; Vered Klinghofer; Loren Lasko; Thomas McGonigal; Qun Li; Saul H Rosenberg; Vincent L Giranda; Yan Luo
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

7.  PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

Authors:  Jean L Nakamura; Amelia Karlsson; Nils D Arvold; Alexander R Gottschalk; Russell O Pieper; David Stokoe; Daphne A Haas-Kogan
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

8.  5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.

Authors:  V Taylor; M Wong; C Brandts; L Reilly; N M Dean; L M Cowsert; S Moodie; D Stokoe
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

9.  Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products.

Authors:  Hua-Chuan Zheng; Yi-Ling Li; Jin-Min Sun; Xue-Fei Yang; Xiao-Han Li; Wei-Guo Jiang; Yin-Chang Zhang; Yan Xin
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 10.  Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Authors:  A Lester; R Rapkins; S Nixdorf; M Khasraw; K McDonald
Journal:  Clin Transl Oncol       Date:  2016-09-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.